

- Clear cell carcinoma, renal, 578, 578t. *See also* Renal cell carcinoma (RCC)
- Clear liquid diet, 95e-5
- Cleidocranial dysplasia, 2455
- Clenched-fist injury, 167e-2, 167e-3t
- CLIA (Clinical Laboratory Improvement Amendments Act), 480e-6
- Climate change, **151e-1**
 adaptation to, 151e-9
 arbovirus infections and, 151e-4–5
 average global temperatures and, 151e-1–2
 El Niño events and, 151e-4, 151e-4f, 151e-8, 151e-8f
 greenhouse gases and, 151e-1, 151e-2f, 151e-2t
 hurricane severity and, 151e-4
 Lyme disease and, 151e-5–6, 151e-6f
 mitigation of, 151e-9
 overview of, 151e-1, 151e-1f
 population displacement and, 151e-8
 population migration and conflict and, 151e-3–4
 precipitation patterns and, 151e-3–4
 sea levels and, 151e-4
 vector-borne disease and, 151e-4–6, 151e-5f, 151e-6f
 waterborne disease and, 151e-6–8, 151e-7f
- Clindamycin
 for acne vulgaris, 352
 for actinomycosis, 1091t
 action of, 931, 931t, 943
 adverse effects of, 246e-3t, 938t, 943
 for anaerobic bacterial infections, 1101, 1102
 for anthrax, 261e-3, 261e-5t
 for asymptomatic pharyngeal GAS carriage, 966
 for *Babesia* infections, 780t, 1386–1387, 1386t
 for bacterial vaginosis, 873t, 875
 for bite-wound infections, 167e-2, 167e-3t, 832t
 for *Capnocytophaga* infections, 183e-3
 for cellulitis, 832, 832t
 for clostridial infections, 991t, 994
 for clostridial myonecrosis, 780t
 for CNS toxoplasmosis, 903
 for deep neck infections, 235
 for endocarditis prophylaxis, 826t
 for gas gangrene, 832t, 991t
 indications for, 246e-3t, 940t, 943
 for Lemierre's disease, 234
 for lung abscess, 815
 for *M. hominis* infections, 926
 for malaria treatment, 1378t
 for MRSA infections, 345, 962t
 for necrotizing fasciitis, 780t, 832t
 for osteomyelitis, 840t, 841t
 for otitis media, 229t
 for PCP, 1361t
 for pelvic inflammatory disease, 879
 for pharyngitis, 232f
 for pneumococcal pneumonia, 953
 in pregnancy and lactation, 246e-3t, 937t
 prophylactic, 945t
 resistance to
 in anaerobic bacteria, 1101
 in group A streptococci, 969
 inducible, 345
 mechanisms of, 931t, 934
 prevalence of, 940t
 for sepsis/septic shock, 1757t
 for sinusitis, 227t
 for skin and soft tissue infections, 768t, 832, 962t
 for streptococcus group B, 50
 for toxic shock syndrome, 780t, 963, 965t, 969
 for toxoplasmosis prophylaxis in HIV infection, 1251t
 for Vincent's angina, 233
- Clinical breast examination, 480, 481t, 524
- Clinical decision-making, 3, 16e-4. *See also* Clinical reasoning
- Clinical Evidence (directory), 25t
- Clinical Laboratory Improvement Amendments Act (CLIA), 480e-6
- Clinical laboratory tests, **480e-1**
 accuracy of, 21, 21t
 analytic sensitivity of, 480e-2
 analytic specificity of, 480e-2
 batteries of, 2
 critical values, 480e-2, 480e-2t
 diagnostic principles of, 480e-2–3
 for disease and treatment monitoring, 480e-1
 for disease diagnosis, 480e-1
 for disease screening, 480e-1
 error sources in, 480e-4–5, 480e-4t
 genetic. *See* Genetic testing
 home, 480e-5
 physician's evaluation and use of, 2–3
 point-of-care, 480e-5
 predictive value of, 22, 479, 479t
 receiver operative characteristic curves for, 21, 22f
 reference values for, 480e-3–4, 480e-3f
 cerebrospinal fluid, 2766t
 cholesterol, 480e-3, 480e-4f
 clinical chemistry and immunology, 2757–2764t
 hematology and coagulation, 2754–2756t
 renal function, 480e-3–4, 480e-4f
 toxicology and therapeutic drug monitoring, 2764–2766t
 urine analysis and renal function, 2768–2769t
 vitamins and trace minerals, 2766t
 regulation of laboratories performing, 480e-6
 for risk assessment, 480e-1
 sensitivity of, 21, 21t, 479, 479t
 specificity of, 21, 21t, 479, 479t
 "stat" orders for, 480e-2–3
- Clinical microbiology laboratory, 150e-1. *See also* Infectious diseases, laboratory diagnosis of; Virus(es), laboratory identification of
- Clinical practice guidelines, 3, 17e-3, 26
- Clinical Pulmonary Infection Score (CPIS), 811, 811t. *See also* Ventilator-associated pneumonia (VAP)
- Clinical reasoning, **18**
 clinical expertise in, 18
 cognitive shortcuts in, 19
 decision support tools, 24
 diagnostic test interpretation and, 21–24. *See also* Clinical laboratory tests
 diagnostic vs. therapeutic, 20
 economic incentives and, 21
 evidence-based medicine and, 24–26
 hypothetico-deductive model of, 20
 influences on, 20–21
 intuitive vs. analytic, 18–20
 pattern recognition in, 18–19
 practice setting and, 21
 practice style and, 20–21
- Clinical research. *See* Research
- Clinical skills, 1–3
- Clinical trials, 25–26, 43, 2025
- Clinical uncertainty, 16e-4
- Clinton Foundation HIV/AIDS Initiative, 12
- CLIP staging, of hepatocellular carcinoma, 546, 546t
- Clitoral engorgement, 330
- Clitoral vacuum device, 331
- CLL. *See* B-cell chronic lymphoid leukemia (CLL)/small lymphocytic lymphoma
- Clobazam, 2553t
- Clobetasol, 347
- Clofarabine, 103e-11t, 683
- Clofazimine
 action of, 205e-7
 adverse effects of, 205e-7, 361, 379, 1126, 1263
 for erythema nodosum leprosum, 1128
 for leprosy, 1126–1127, 1127t
 for TB, 205e-7
- Clofibrate, 2199, 2218t
- Clomiphene citrate, 7e-4, 337, 2389
- Clomipramine, 190, 2710t, 2714
- Clonal eosinophilia, 135e-7
- Clonality, of stem cells, 454
- Clonazepam
 adverse effects of, 2553t
 for anxiety disorders, 2711t
 for ataxia/tremor, 2672
 for dyspnea, 62t
 for epilepsy, 2553t
 for glossodynia, 239
 for myoclonus, 2623
 overdose/poisoning with, 473e-10t, 2764t
 for pain, 91t
 for panic disorder, 2709
 pharmacology of, 2711t
 for posthypoxic myoclonus, 1782
 for REM sleep behavior disorder, 193
 for sleep disorders in PD, 2618
 for status epilepticus, 2558f
 for tardive dyskinesia, 2624
 therapeutic monitoring of, 2764t
 for vertigo, 151t
- Clonidine
 adverse effects of, 253t, 1467t, 2640t
 for ascites, 288
 for diabetic diarrhea, 272
 drug interactions of, 41
 for hot flashes, 623
 for hypertension, 1624t
 for hypertensive emergencies, 1627
 for inappropriate sinus tachycardia, 1477
 for menopausal symptoms, 2383
 for opioid withdrawal syndrome, 468e-3
 overdose/poisoning with, 473e-9t
 for pain, 61
 perioperative, 54
 for smoking cessation therapy, 507, 2732
 for Tourette's syndrome, 2623
- Clonidine suppression test, 2330
- Cloning, 441, 454
- Clonorchis sinensis*/clonorchiasis. *See also* Biliary (hepatic) flukes
 clinical features of, 1428
 diagnosis of, 245e-2t, 245e-5t, 245e-6t, 765t
 epidemiology of, 245e-2t, 765t, 1428
 life-cycle hosts of, 245e-2t
- Clopidogrel
 action of, 746f, 747
 adverse effects of, 404, 729, 747, 1864
 with aspirin, 747, 2570
 for cardiac catheterization pretreatment, 1461
 dosage of, 747
 drug interactions of, 205e-3, 1921
 genetic variations in response to, 39t, 40, 43, 277, 277t, 742–743, 743t, 1596
 indications for, 747l
 for ischemic heart disease, 1590
 management before endoscopic procedures, 1889t
 management before lumbar puncture, 443e-1
 metabolism of, 34t, 35
 for myocardial infarction
 NSTEMI-ACS, 1596, 1598, 1598t
 as secondary prevention, 1610
 STEMI, 1606
 in PCI, 296e-1, 296e-2, 1596
 in peripheral artery disease, 1644
 resistance to, 747
 for stroke/TIA prevention, 2569–2570
- Clorazepate, 2711t
- Closed-loop obstruction, 1982. *See also* Intestinal obstruction
- Clostridial myonecrosis. *See* Gas gangrene (clostridial myonecrosis)
- Clostridium* spp., 990, 990f, 1096
- Clostridium baratii*, 987
- Clostridium botulinum*, 261e-8, 987. *See also* Botulism
- Clostridium butyricum*, 987
- Clostridium difficile*, 145e-9, 857–858
- Clostridium difficile*-associated disease
 antibiotics associated with, 858
 in cancer, 488, 1798
 clinical features of, 266t, 859
 diagnosis of, 770–771, 856, 859, 859t
 with enteral feeding, 98e-9
 epidemiology of, 855, 857–858